Thomas Civik - 07 Oct 2021 Form 3 Insider Report for Pyxis Oncology, Inc. (PYXS)

Reporting relationship: Director
Issuer ticker: PYXS
Reported as of: 07 Oct 2021
Net transaction value: $0
SEC form: 3
Accepted by SEC: 07 Oct 2021, 21:00:06 UTC
Prior SEC filing: 09 Sep 2021
Next SEC filing: 18 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ Pamela Connealy, Attorney-in-Fact for Thomas Civik

Filing notes and source

Key filing fact

Thomas Civik filed Form 3 for Pyxis Oncology, Inc. (PYXS) on 07 Oct 2021.

Key facts

This page summarizes Thomas Civik's Form 3 filing for Pyxis Oncology, Inc. (PYXS).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Oct 2021, 21:00.

Change

Previous filing in this sequence was filed on 09 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PYXS holding Derivative

Stock Option (Right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 07 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,725
Exercise price: $8.71
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These stock options vest in three, substantially-equal annual installments beginning on the first anniversary of the August 19, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC remarks

Exhibit List: Exhibit 24 - Power of Attorney